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Abstract: For many viruses, one or two proteins enable cell binding, membrane fusion and 
entry. The large number of proteins employed by poxviruses is unprecedented and may be 
related to their ability to infect a wide range of cells. There are two main infectious forms 
of vaccinia virus, the prototype poxvirus: the mature virion (MV), which has a single 
membrane, and the extracellular enveloped virion (EV), which has an additional outer 
membrane that is disrupted prior to fusion. Four viral proteins associated with the MV 
membrane facilitate attachment by binding to glycosaminoglycans or laminin on the cell 
surface, whereas EV attachment proteins have not yet been identified. Entry can occur at 
the plasma membrane or in acidified endosomes following macropinocytosis and involves 
actin dynamics and cell signaling. Regardless of the pathway or whether the MV or EV 
mediates infection, fusion is dependent on 11 to 12 non-glycosylated, transmembrane 
proteins ranging in size from 4- to 43-kDa that are associated in a complex. These proteins 
are conserved in poxviruses making it likely that a common entry mechanism exists. 
Biochemical studies support a two-step process in which lipid mixing of viral and cellular 
membranes is followed by pore expansion and core penetration. 
Keywords: vaccinia virus entry; viral membrane fusion; endocytosis; macropinocytosis; 
transmembrane proteins 
 
1. Introduction 
Poxviruses comprise a family of genetically related, large, enveloped, DNA viruses that replicate 
exclusively within the cytoplasm of vertebrate or invertebrate cells [1]. Homologs of approximately 
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100 of the 200 or more genes are present in all Chordopoxviruses and 50 are recognizable in both 
Chordopoxviruses and Entomopoxviruses [2]. The products of the highly conserved genes are involved 
in cell entry, gene expression, DNA replication, intramolecular disulfide bond formation and virion 
assembly; products of the less conserved genes participate in specific host interactions. The most 
intensively studied poxviruses belong to the Orthopoxvirus genus, including variola virus (causative 
agent of smallpox, eradicated from nature), vaccinia virus (VACV; the modern smallpox vaccine, now 
endemic in Brazil), cowpox virus (the original smallpox vaccine, indigenous in Europe, occasionally 
infects humans) and monkeypox virus (indigenous in Africa, causes a smallpox-like disease of 
humans). Studies of VACV have provided most of what we know about poxvirus entry [3]. 
For historical reasons, VACV genes and open reading frames are commonly identified with a 
capital letter (representing a HindIII restriction endonuclease genome fragment), an arabic number 
(representing the position within the HindIII fragment) and L or R (indicating transcription to the left 
or right, respectively). Proteins have the corresponding designation except that L or R is omitted. For 
example L1 is the protein encoded by L1R. The www.poxvirus.org is a useful website for correlating 
these common names, which are listed for the Copenhagen strain of VACV, with GenBank 
annotations for other VACV strains such as Western Reserve (WR). 
2. Poxvirus Replication Cycle  
DNA viruses typically replicate and express their genomes in the nucleus making extensive use of 
cellular proteins. In contrast, poxviruses rely heavily on virus-encoded proteins enabling them to 
replicate in the cytoplasm [1]. The infectious VACV membrane-bound particle contains a core, within 
which reside the linear, double-stranded DNA genome and virus-encoded enzymes and factors that 
allow transcription of the early set of genes. When the core enters the cytoplasm, early mRNA and 
protein synthesis occur, followed by DNA replication [4a]. The replicated DNA provides a template 
for the synthesis of intermediate and late classes of mRNA. The most recent analysis of VACV WR 
suggests that there are 118 early, 53 intermediate and 38 late genes [4b]. Following late gene 
expression, virus assembly begins. The initial infectious form, called a mature virions (MV) [5], has a 
single external membrane [6–8] (Figure 1). Some MVs are wrapped in a modified trans-Golgi or 
endosomal membrane to become triple-membrane particles called wrapped virions (WVs), whereas 
other MVs remain free or in inclusions within the cytoplasm until liberated by cell lysis [9–11]. The 
WVs are transported on microtubules to the periphery of the cell where the outer membrane fuses with 
the plasma membrane to release an extracellular enveloped virion (EV), consisting essentially of a MV 
with one additional membrane [12,13] (Figure 1). At least 20 proteins are associated with the MV 
membrane and 6 others with the outer EV membrane. In older papers and some recent ones, MVs may 
be referred to as INVs or IMVs; WVs as IEVs; and EVs as EEVs and CEVs. Viruses 2012, 4  690 
 
 
Figure 1. Two major forms of infectious virions. The mature virion (MV) contains more 
than 80 proteins and consists of a nucleoprotein core surrounded by a lipid membrane 
(black) with about 20 proteins. Approximately 20 proteins within the core are devoted to 
synthesis and modification of mRNA. The enveloped virion (EV) consists essentially of a 
MV with an additional membrane (red) containing about 6 proteins distinct from those in 
the MV membrane. 
 
 
MVs are very stable and are thought to mediate transmission between host animals, whereas EVs 
have a fragile outer membrane and are specialized for exiting the intact cell and spreading within the 
host. EVs can remain associated with the tips of actin-containing protrusions at the cell surface or 
released into the surrounding fluid but the former are predominant in most VACV strains and are 
largely responsible for cell-to-cell spread [14–18]. However, a few VACV strains, such as IHD-J, 
release relatively large numbers of EVs [19]. Enhanced EV release may be a tissue culture adaptation 
of some VACV strains. The difference in the amounts of EVs released by WR and IHD-J is largely 
due to a single amino acid change in the A34 EV membrane protein [20]. Mutations of other EV 
proteins can also increase EV release [21]. Partly for technical reasons, the majority of entry studies 
have been carried out with MVs, usually of the WR VACV strain. A high percentage of EVs that are 
released from cells have a partly disrupted outer membrane, making experiments with these particles 
difficult to interpret. There have been virtually no investigations of entry mediated by cell-associated 
EVs, despite their biological importance.  Viruses 2012, 4  691 
 
 
3. Entry Pathways 
Entry of the core or nucleoprotein of enveloped viruses requires fusion of the viral membrane with 
either the plasma or endosomal membrane [22]. The latter route is thought to provide an advantage in 
providing passage through the dense cell cortex. For VACV, it is necessary to consider the existence of 
two infectious forms of virus, the single-membrane MV and the double-membrane EV. On theoretical 
grounds alone it seemed unlikely that the outer EV membrane would fuse since that would leave a 
membrane bound MV-like particle in the cytoplasm. Indeed, some electron microscopic images show 
fusion of the single MV membrane with the plasma membrane of the cell [23–25]. Moreover, electron 
microscopic images show MVs fusing with plasma membrane after dissolution of the EV membrane, 
apparently by interaction with glycosaminoglycans at the cell surface [26].  
In addition to the above images of VACV fusing with the plasma membrane, other images show 
MVs within endosomes [27,28]. Further microscopic (Figure 2) and biochemical studies indicate that 
VACV MVs can enter cells via neutral pH plasma membrane or low pH endocytic pathways [25]. The 
strong enhancement of entry following brief low pH (<6) treatment of cell-bound virions (mimicking 
the low pH of late endosomes) and inhibition of entry by preventing acidification of endosomes 
(Figure 3) suggests that the endocytic route is dominant for the WR strain of VACV [25].  
Figure 2. Transmission electron micrographs showing a VACV MV fusing with the 
plasma membrane (A) and endosomal membrane (B). Prior to cryosectioning, the infected 
cells were stained with a monoclonal antibody to the MV membrane protein D8 followed 
by protein A conjugated to gold spheres. Modified from reference [25]. 
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Figure 3. Effects of low pH and inhibitors of endosomal acidification on VACV MV entry. 
(A) Following adsorption of a recombinant VACV MV that expresses firefly luciferase at  
4 °C, cells were incubated with buffers at the indicated pH for 3 min at 37 °C. The cells 
were then incubated with regular medium for 1 h at 37 °C, lysed and luciferase activity 
measured; (B) Cells were pretreated with indicated concentrations of bafilomycin A1 for 
50 min at 37 °C and then infected with MVs, briefly exposed to pH 5 or 7.4 buffer, and 
luciferase activity measured as in panel A. Note that incubation at pH 5 allows fusion at the 
plasma membrane and bypasses the effect of the inhibitor. Modified from reference [25]. 
 
Low pH as well as brief proteinase treatment can stably activate MVs prior to their adsorption to 
cells suggesting a triggering or unmasking effect, but these procedures do not alleviate sensitivity to 
inhibitors of endosomal acidification [29]. Entry of some other VACV strains, such as IHD-J, are  
not accelerated by low pH or inhibited by lysomotropic agents indicating entry through the plasma 
membrane or a neutral pH endocytic route [30]. Adaptation of entry pathways could have occurred 
during extensive cell culture passaging of VACV strains. Several recently isolated orthopoxviruses 
have been shown to be more similar to WR than IHD-J with regard to entry pathway, emphasizing the 
importance of the endocytic route (Z. Bengali, P.S. Satheshkumar and B. Moss, unpublished). There 
have been few studies of members of other poxvirus genera. Myxoma virus entry is not enhanced by 
low pH [31].  
Recent evidence suggests that the VACV A25 and A26 proteins serve as fusion suppressors for 
MVs and determine strain-specific virus entry pathways [32]. Thus, MVs containing functional A25 
and A26 proteins do not fuse readily with the plasma membrane and enter through the endocytic 
pathway, whereas those missing these proteins enter through the plasma membrane. Further discussion 
of these proteins and mechanistic aspects of the model will be presented below. The route of infection 
also depends on the cell type [30,33]. VACV can even enter insect cells, though replication is abortive [34–
36]. Entry into Drosophila S2 cells is exclusively through the endocytic route [36]. 
Engulfment of the large VACV MV particles occurs by clathrin- and caveolin-independent 
macropinocytosis or fluid phase endocytosis and is dependent on actin dynamics and cell   
signaling [37–39]. The requirement for cell signaling may have led to earlier proposals that chemokine 
receptors serve as poxvirus entry portals [40–42]. Two cellular proteins, VPEF and CD98, associated 
with lipid rafts participate in the fluid phase uptake of MVs [37,43]. EVs may enter through the plasma 
membrane or following endocytosis [26,44,45].  Viruses 2012, 4  693 
 
 
The infectivity of intact and detergent extracted MVs can be enhanced by incubation with 
liposomes containing phosphatidylserine [46,47]. This finding was recently confirmed and extended 
by Mercer and Helenius [37], who also showed that annexin 5 inhibits VACV entry. They proposed 
that the role of phosphatidylserine in MV endocytosis is similar to the role of this lipid in uptake of 
apoptotic bodies. The infectivity of lipid-extracted MVs could also be enhanced by the non-biologically 
relevant D-stereoisomer of phosphatidylserine as well as by other phospholipids that are not known to 
signal uptake of apoptotic debris [48]. Therefore, the putative lipid receptor would have low specificity 
suggesting a role for bridging molecules. A soluble protein called Gas6 can bridge phosphatidylserine 
and the TAM receptor tyrosine kinase Axl on certain cells [49]. However, Gas6 had little or no effect 
on MV entry, although EV entry was enhanced [49]. Paradoxically, annexin 5 was reported not to 
inhibit EV entry, suggesting that phosphatidylserine is not involved [45]. Further studies are needed to 
understand the role of lipids in VACV entry. 
4. Attachment 
Proteinase treatment of cells can prevent binding of MVs suggesting a role for cell surface   
proteins [50,51]. Four viral proteins can mediate MV attachment. D8 binds chondroitin sulfate [52] 
and A27 and H3 proteins bind heparan sulfate [53–56] indicating the importance of 
glycosaminoglycans (Table 1). Heparin appears to have a greater inhibitory effect on VACV strains 
that preferentially enter by a neutral pH mechanism [30]. The A26 protein binds laminin [57]. Of  
the four attachment proteins, only H3 is highly conserved among poxviruses. D8 and H3 have 
transmembrane domains; the A26 and A27 proteins interact with each other and the latter is   
anchored by the A17 transmembrane protein, which is an important structural element of the MV 
membrane [58–60]. The attachment proteins are multifunctional and are not individually essential, 
though deletion of A27 and H3 severely reduce VACV infectivity [55,61,62]. H3 also participates in 
MV assembly and A27 is required for formation of the WV. In addition, the A26 protein mediates the 
incorporation of MVs into so-called A-Type cytoplasmic inclusion bodies of some orthopoxviruses 
including cowpox virus and ectromelia virus [63]. The A25 protein of VACV, recently described as a 
fusion suppressor [32], is a truncated form of the A-type inclusion protein [64,65]. A soluble, 
truncated, recombinant form of the L1 protein, described below, can attach to cells lacking 
glycosaminoglycans and prevent VACV entry suggesting that it is a receptor binding protein [66]. 
However, the putative cellular protein interacting with L1 remains to be determined. The binding of 
EVs was not diminished by proteinase treatment of cells and the attachment molecules have not been 
identified [50]. Viruses 2012, 4  694 
 
 
Table 1. VACV MV attachment and entry proteins. 
Protein kDa TM 
a Expr 
b Cons 
c Properties 
Attachment 
A26  58  -  L  -  Binds laminin; assoc. with A27 
A27  13  -  I  -  Binds heparan; assoc with A17; N 
d  
D8  35  N  I  -  Binds chondroitin; N  
H3 38  C  I  P  Binds  heparan;  N 
Entry 
A16 43  C  I  P  EFC 
e; paralog G9, J5; binds G9; C-C 
f 
A21 14  N  L  P  EFC;  C-C 
A28  16  N  L  P  EFC; N; binds H2; C-C 
F9 24  C  L  P  EFC  associated;  C-C 
G3  13  N  L  P  EFC; binds L5 
G9  39  C  L  P  EFC; paralog A16, J5; binds A16; C-C 
H2  22  N  L  P  EFC; binds A28; C-C 
I2 8  C  L  C  EFC? 
J5  15  C  L  P  EFC; paralog A16, G9; C-C 
L1  27  C  L  P  EFC associated; N; C-C; Myr 
g 
L5  15  C  L  P  EFC; binds G3; C-C 
O3 4  N  I  C  EFC 
a TM, N- or C-terminal transmembrane domain; 
b Expr, expressed at I (intermediate) or L (late) 
times of replication; 
c Cons, conserved in all poxviruses (P) or all chordopoxviruses (C); 
d N, target 
of neutralizing antibody; 
e EFC, component of entry-fusion complex; 
f C-C, intramolecular 
disulfide bond(s); 
g Myr, myristoylated. 
5. Identification of Viral Proteins that Mediate Core Entry 
Although many enveloped viruses encode one or two proteins that are sufficient to mediate 
attachment and entry, VACV is exceptional. Thus far, 11 to 12 proteins have been implicated in a  
post-attachment entry step (Table 1). These proteins are conserved in all poxviruses with the possible 
exception of O3; although the small size of the latter protein makes it difficult to detect statistically 
significant homology, all chordopoxviruses encode a protein with similar features at the same genome 
location as O3 [67]. Entry proteins were originally discovered by identifying genes predicted to encode 
transmembrane proteins that are conserved in all poxviruses, constructing inducible mutants, and 
determining their phenotypes [68–70]. MVs that formed in the absence of inducer, and therefore 
lacking the specific target protein, could bind to cells but had low infectivity and the cores did not 
enter the cytoplasm as determined by microscopy. Furthermore, cells infected with the mutant viruses 
were unable to form syncytia following a low pH pulse. Additional entry proteins conserved in all 
poxviruses were identified by mass spectroscopy of complexes captured with antibodies to the above 
entry proteins [71] and subsequently confirmed by constructing conditional lethal mutants. Presently, 
nine proteins (A16 [72], A21 [69], A28 [68,73], G3 [71,74,75], G9 [76], H2 [77,78], J5 [79], L5 [70] 
and O3 [67,80]) are considered to be integral components of the entry fusion complex (EFC) and two 
more, F9 [81] and L1 [82], have been designated EFC-associated. The phenotypes resulting from 
failure to express the integral or associated EFC proteins are similar and the distinction is based mainly Viruses 2012, 4  695 
 
 
on their contribution to the stability of the complex, which may depend on their relative locations and 
subunit interactions. The EFC proteins are synthesized following viral DNA replication and are 
dedicated to entry, since in their absence normal looking virions that are competent to synthesize 
mRNA in vitro but are unable to initiate an infection, are assembled. 
The involvement of several additional VACV proteins in entry has been proposed. The phenotype 
of a conditional lethal I2L mutant is similar to that of EFC mutants and the I2 protein is listed in  
Table 1 [83]. However, the repression of I2 expression results in diminished amounts of EFC proteins 
in the viral membrane, raising the possibility of an indirect effect on entry [83] and association of I2 
with the EFC has not been demonstrated. The heterologous expression of A17 was reported to cause 
fusion of transfected cells suggesting a similar role during entry [84]. A17 is a major component of the 
virion membrane and conditional lethal A17 mutants are blocked in viral membrane formation [85,86], 
where fusion may have a role, making it difficult to confirm an additional entry function. 
6. Organization of the EFC and Structure of Subunit Proteins 
The EFC has been isolated by immunoaffinity capture from non-ionic detergent-treated cytoplasmic 
extracts and membrane fractions of VACV-infected cells, probably representing immature virions [71]. 
The EFC fails to form when formation of the viral membrane is inhibited [71], thus preventing its 
synthesis in heterologous systems and hindering its physical characterization. The proteins are tightly 
bound to the membrane of the MV, making it difficult to extract as a complex even with non-ionic 
detergents, explaining why the infectivity of detergent extracted MVs can be partially reconstituted 
with lipids [47]. The EFC is destabilized when synthesis of any one of the nine integral component 
proteins is prevented, suggesting that it is held together by multiple subunit interactions. However, 
under destabilizing conditions, some subunit interactions are retained; these include interactions of 
A28 to H2 [78], A16 to G9 [87] and G3 to L5 [88] (Table 1). As will be detailed in a subsequent 
section, A16:G9 can also bind to the A56:K2 heterodimer of fusion regulatory proteins [87] and the 
A26 protein [119].  
The entry proteins vary in size from 4- to 43-kDa, are non-glycosylated, and resemble neither type 
1- nor type 2-fusion proteins of other viruses (Table 1). The combined mass of the EFC and   
EFC-associated proteins is 232 kDa, assuming each component is represented once. Five of the 
proteins, comprising A21, A28, G3, H2 and O3 have a N-terminal transmembrane domain; the others 
consisting of A16, F9, G9, J5, L1 and L5 have a C-terminal transmembrane domain. Interestingly, 
A16, G9, and J5 are related in sequence and apparently the progenitor was duplicated and diverged 
early in poxvirus evolution. Similarly, L1 and F9 are structurally related. Nevertheless each paralog is 
encoded by all poxviruses and is individually required for entry. With the exceptions of O3, G3 and I2, 
the entry proteins contain conserved intramolecular disulfide bonds that are formed by a novel 
cytoplasmic redox system that is encoded by all poxviruses [89]. No other viral proteins are known 
substrates of the poxvirus redox system, suggesting co-development with the EFC proteins perhaps 
because of their cytoplasmic domains. The cellular redox system, in contrast to the poxvirus system, is 
localized in the endoplasmic reticulum. The possibility that disulfide interchange has a role in 
activation of the EFC to initiate fusion is an intriguing thought, as this has been suggested for some 
other viruses [90–93]. Viruses 2012, 4  696 
 
 
Remarkably, O3 consists of only 35 amino acids, making it the smallest protein encoded by   
VACV [80]. The homologs in other poxviruses range from 29 to 48 amino acids in length and have a 
low degree of amino acid identity yet can complement an O3 deletion mutant [67]. The characteristic 
feature of the O3 homologs is the N-terminal transmembrane domain, which is essential and sufficient 
for its association with other EFC proteins [67].  
Mutagenesis of the H2 protein defined a highly conserved region that is important for interaction 
with the A28 protein [78]. The A28 protein is a target of neutralizing antibodies [94] indicating an 
exposed location on the surface and its immunogenicity is specifically enhanced by association with 
H2 [95]. 
The EFC-associated L1 protein has been subjected to detailed analysis. L1 is a target of potent 
neutralizing antibodies indicating that it is exposed on the MV surface [96,97]. The protein is 
myristoylated at the N-terminal glycine residue [98,99] and contains three intramolecular disulfide 
bonds [89,100]. Mutation of the N-terminal glycine prevents the complementation of VACV 
infectivity [101], alters the intracellular localization of L1 as determined by confocal microscopy and 
reduces intramolecular disulfide bond formation [102], although the protein still associates with the 
EFC and MVs [103]. The crystal structure reveals a fold composed of a bundle of -helices packed 
against a pair of two-stranded -sheets [104]. The 7D11 neutralizing monoclonal antibody binds to a 
discontinuous epitope containing two loops that are held together by a disulfide bond [105]. 
Interestingly, there is a large hydrophobic cavity that could accommodate the N-terminal myristate 
moiety [104] and recent studies indicate that mutations within the cavity inhibit infectivity without 
affecting myristoylation [103]. Taken together, these results suggest a “myristate switch” model in 
which the acyl chain is released from the cavity during entry. 
7. Membrane Fusion 
Entry of the nucleoprotein or core of enveloped viruses is usually divided into three steps: close 
apposition of the viral and cellular membrane, lipid-mixing of the outer membrane leaflets leading to 
the formation of a hemifusion intermediate, and formation and expansion of a pore [22]. The lipid-
mixing step can be studied by loading the virion membrane with a self-quenching lipophilic dye such 
as R18 and measuring an increase in fluorescence. Fusion of VACV MVs and EVs with cells was 
demonstrated in that way [106]. By using recombinant VACV expressing firefly luciferase regulated 
by an early promoter, it has been possible to distinguish lipid-mixing and later steps dependent on core 
entry (Figure 4).  Viruses 2012, 4  697 
 
 
Figure 4. Membrane fusion and core entry. R18-loaded MVs that express firefly luciferase 
were incubated with HeLa cells at 4 °C to permit binding. Washed cells were then placed 
in a cuvette containing pre-warmed media at 37 °C and fluorescence was monitored over 
time (red line; left y-axis). In parallel, unlabeled MVs were bound to cells in the cold and 
then shifted to 37 °C. Cell lysates were prepared at indicated times and assayed for 
luciferase (LUC) activity (purple line; right y-axis). Modified from ref [107]. 
 
The roles of individual EFC and EFC-associated proteins were investigated using MVs deficient in 
a single component, derived from a panel consisting of 10 conditional lethal inducible mutants [107]. 
The mutant virions were all able to attach to cells but most were unable to carry out even the initial 
lipid-mixing step. However, lipid-mixing occurred with the A28, L1 and L5 mutants but further steps 
did not. Two possibilities were considered: one is that the latter proteins are specifically required for 
pore formation or expansion; the other is that traces of A28, L1 and L5 remain in the MVs (though 
undetectable by Western blotting) and that this is sufficient for lipid mixing but not pore formation. 
Interestingly, neutralizing 7D11 monoclonal antibody to L1 also allows lipid mixing but not core  
entry [107]. Regardless of which hypothesis is correct, the data support a two-step model in which 
lipid mixing of the outer leaflets of the viral and cellular membranes occurs followed by merging of 
the inner leaflets and expansion of the pore to permit core entry.  
Although low pH accelerates entry of MVs as measured by the luciferase assay [25,29], lipid 
mixing is not enhanced by low pH [106,107]. Inhibitors of tyrosine protein kinases, dynamin GTPase 
and actin dynamics have little effect on binding of virions to cells but impair membrane fusion 
measured with R18, whereas partial cholesterol depletion and inhibitors of endosomal acidification and 
membrane blebbing have a more severe effect at the later stage of core entry [107]. Extensive actin 
remodeling and mobilization occur during MV binding to cell surfaces [37,38,108] suggesting that 
actin-enriched projections enhance the intimacy of membrane contact allowing virus-cell membrane Viruses 2012, 4  698 
 
 
fusion. Actin remodeling has been proposed to facilitate fusion by forcing membranes together and 
enlarging pores in a variety of systems [109–111] including viral protein-induced cell-cell fusion and 
virus entry [112–117]. In HIV entry, actin remodeling has a more important role in pore expansion and 
content mixing than hemifusion [118,119]. Cytochalasin D and latrunculin have a greater inhibitory 
effect on VACV core entry than hemifusion, suggesting that actin dynamics may be required for both 
hemifusion and pore formation [107]. 
8. Cell-Cell Fusion 
Infection with certain VACV mutants causes cells to form syncytia. The mutations are in the   
A56R [120] and K2L [121–123] genes. Although referred to as fusion from within, syncytia formation 
is dependent on the formation and externalization of virions and on components of the EFC suggesting 
that the phenomenon has features related to virus entry [124]. A56 and K2 form a complex on the 
plasma membrane and the EV membrane [125]. This complex can interact with the A16 and G9 
subunits of the EFC to prevent spontaneous activation of the fusion apparatus by progeny virions [87]. 
Uninfected cells expressing A56 and K2 but neither alone are resistant to forming syncytia when 
mixed with cells infected with an A56R deletion mutant [126]. Therefore, the A56-K2 complex acts as 
a fusion suppressor. 
Wild type VACV-infected cells can also form syncytia if they are briefly exposed to low   
pH [106,127], similar to that occurring at neutral pH with A56R and K2L mutants. This process has 
also been called fusion from within, although again it is dependent on virions on the cell surface [128] 
and the EFC [68–70]. The low pH may assist in removing the outer EV membrane [129] and 
synchronizing the fusion process [3]. Low pH can also induce syncytium formation immediately after 
infection with a high multiplicity of MVs and this has been called fusion from without [127]. A recent 
report demonstrates that the A26 protein, like A56-K2, binds to the A16 and G9 components of the 
EFC, that this association is weakened by low pH, and that A26 deletion mutants can induce fusion 
from without at neutral pH [130].  
9. Inhibition of Superinfection 
VACV employs mechanisms to prevent superinfection of previously infected cells by MVs [131–133]. 
Superinfection exclusion operates between virus adsorption and early gene expression and is nearly 
complete by 6 h. Recent studies show that this early exclusion phenomenon occurs at the lipid-mixing 
step and is not dependent on expression of A56 (Laliberte, J. and Moss, B., unpublished). The association 
of the A16 and G9 components of the EFC with the A56-K2 complex, however, suggests that the latter 
represents a second mechanism of preventing superinfection as well as syncytia formation. A56 and 
K2 expressed by infected cells reduces the entry of superinfecting virus at late times, apparently on top 
of the already reduced superinfecton exclusion [134]. Moreover, uninfected cells stably expressing 
A56 and K2 are resistant to infection indicating that these proteins are sufficient for superinfection 
exclusion [126]. 
Superinfection exclusion also operates at the level of EVs [135]. Incorporation of VACV early 
proteins A33 and A36 into the plasma membrane leads to repulsion of superinfecting EVs providing a 
mechanism for the rapid spread of infection. Viruses 2012, 4  699 
 
 
10. Final Thoughts 
VACV has the remarkable ability to infect a wide variety of cells including those of insects, birds 
and mammals, although in some cases the infection is aborted following early gene expression. 
Perhaps the ability to infect diverse cells is a benefit of the complex poxvirus fusion apparatus and the 
use of alternative entry pathways. A subject that has been largely absent from this review is the 
existence of specific cell receptors that directly activate the viral fusion apparatus. The wide variety of 
permissive cells could suggest multiple or ubiquitous receptors, which would make it difficult to 
identify them, or alternatively the absence of such receptors. It would not be the first situation in which 
poxviruses demonstrate reliance on their own proteins e.g., they encode their own enzymes for gene 
expression, DNA replication, and disulfide bond formation. At least 11 VACV proteins are dedicated 
to post-attachment steps in MV entry. Although conserved in all poxviruses, these proteins have no 
non-poxvirus homologs nor do they resemble fusion proteins of other viruses. The combined mass of 
the EFC and EFC-associated proteins is 232 kDa and it is possible that several of the small proteins 
together form a non-linear hydrophobic face that comprises a fusion domain. A high-resolution 
structure of the EFC is sorely needed. The mechanism used by cell-associated EVs to enter neighboring 
cells is another area requiring further research. This process could be investigated using live cell 
imaging. Hopefully, the next review of poxvirus entry will address why so many proteins are needed 
rather than how many. 
Addendum 
After completion of this manuscript, a related review that emphasizes poxvirus cell entry pathways 
was published [136]. 
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